Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:BCEL NASDAQ:IMNN NASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.18+9.4%$0.24$0.15▼$13.00$14.28M0.037.27 million shs3.23 million shsBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/AIMNNImunon$5.75+1.8%$7.32$4.83▼$41.22$14.03M2.29382,569 shs44,294 shsNXTCNextCure$5.30-2.7%$5.12$2.69▼$19.20$14.19M1.2750,468 shs2,456 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-3.15%-34.88%-33.55%-24.28%+16,279,900.00%BCELAtreca0.00%0.00%0.00%0.00%0.00%IMNNImunon+0.89%-1.22%-17.40%-73.66%-65.76%NXTCNextCure-0.91%+10.12%+12.40%-33.43%-66.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.18+9.4%$0.24$0.15▼$13.00$14.28M0.037.27 million shs3.23 million shsBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/AIMNNImunon$5.75+1.8%$7.32$4.83▼$41.22$14.03M2.29382,569 shs44,294 shsNXTCNextCure$5.30-2.7%$5.12$2.69▼$19.20$14.19M1.2750,468 shs2,456 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-3.15%-34.88%-33.55%-24.28%+16,279,900.00%BCELAtreca0.00%0.00%0.00%0.00%0.00%IMNNImunon+0.89%-1.22%-17.40%-73.66%-65.76%NXTCNextCure-0.91%+10.12%+12.40%-33.43%-66.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.002,145.93% UpsideBCELAtreca 0.00N/AN/AN/AIMNNImunon 2.75Moderate Buy$232.503,943.48% UpsideNXTCNextCure 2.67Moderate Buy$25.50381.59% UpsideCurrent Analyst Ratings BreakdownLatest BCEL, IMNN, ABP, and NXTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025NXTCNextCurePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$36.00 ➝ $15.007/8/2025NXTCNextCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K78.02N/AN/A($0.29) per share-0.61BCELAtrecaN/AN/AN/AN/A$2.01 per shareN/AIMNNImunon$500K28.06N/AN/A$3.82 per share1.51NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-241.16%N/ABCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/AIMNNImunon-$18.62M-$12.95N/AN/AN/AN/A-405.07%-158.41%11/6/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)Latest BCEL, IMNN, ABP, and NXTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ABPAbproN/A-$0.04N/A-$0.05N/AN/A8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ALatest BCEL, IMNN, ABP, and NXTC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/28/2025IMNNImunonquarterly$0.158.57%8/7/20258/7/20258/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.150.15BCELAtrecaN/A1.581.58IMNNImunonN/A1.301.30NXTCNextCureN/A3.713.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%BCELAtreca37.47%IMNNImunon4.47%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%BCELAtreca11.30%IMNNImunon5.96%NXTCNextCure17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1580.17 million63.49 millionN/ABCELAtreca13039.62 million35.15 millionOptionableIMNNImunon302.44 million2.30 millionNot OptionableNXTCNextCure902.68 million2.20 millionOptionableBCEL, IMNN, ABP, and NXTC HeadlinesRecent News About These CompaniesNextCure to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | bakersfield.comBNextCure Reports Q2 2025 Results and Strategic UpdatesAugust 7, 2025 | tipranks.comNextCure (NXTC) Q2 Loss Widens 71%August 7, 2025 | fool.comNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comNextCure presents new preclinical data on osteogenesis imperfecta treatmentJuly 25, 2025 | msn.comNextCure stock soars after positive data for bone disease treatmentJuly 25, 2025 | investing.comNextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease TreatmentJuly 25, 2025 | msn.comPreclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis ImperfectaJuly 24, 2025 | globenewswire.comNextCure, Inc. (NXTC) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comNextCure shareholders approve board elections and reverse stock split proposalJune 25, 2025 | uk.investing.comNextCure shareholders approve board elections and reverse stock split proposal - Investing.comJune 25, 2025 | investing.comNextcure stock drops near 30% on $745M ADC deal with SimcereJune 18, 2025 | bioworld.comBNextCure Joins China-ADC Gold Rush with $745M Simcere DealJune 17, 2025 | biospace.comBNextCure tanks as it teams up with Simcere on novel ADCJune 17, 2025 | thepharmaletter.comTNextCure advances ADC pivot with $745M deal for Simcere’s phase 1 drugJune 16, 2025 | fiercebiotech.comFNextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% DeclineJune 16, 2025 | msn.comNextCure signs up to $745 million deal with China's Simcere to develop cancer drugJune 16, 2025 | reuters.comNextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6June 16, 2025 | globenewswire.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...May 30, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCEL, IMNN, ABP, and NXTC Company DescriptionsAbpro NASDAQ:ABP$0.18 +0.02 (+9.40%) As of 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Atreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Imunon NASDAQ:IMNN$5.75 +0.10 (+1.77%) Closing price 04:00 PM EasternExtended Trading$5.82 +0.08 (+1.30%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.NextCure NASDAQ:NXTC$5.30 -0.15 (-2.67%) Closing price 03:50 PM EasternExtended Trading$5.38 +0.08 (+1.51%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
